Phase 2 study of talabostat and cisplatin in stage IV melanoma.

被引：0
|
作者：
Uprichard, MJ
O'Day, SJ
Pavlick, AC
Richards, DA
Frenette, G
Stephenson, J
Anthony, S
Pacciucci, PA
Vrhovac, V
Cunningham, C
机构：
[1] Point Therapeut, Boston, MA USA
[2] Inst Canc Res, Med Grp, Los Angeles, CA USA
[3] NYU, Kaplan Canc Ctr, New York, NY 10016 USA
[4] Tyler Canc Ctr, Tyler, TX USA
[5] Carolinas Med Ctr, Charlotte, NC USA
[6] Canc Ctr Carolinas, Greenville, SC USA
[7] Canc Ctr NW, Spokane, WA USA
[8] Mary Crowley Med Res Ctr, Dallas, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：725S / 725S
页数：1
相关论文
共 50 条
  • [31] Phase II, randomized multi-center study of MOX-010 alone or in combination with dacarbazine (DTIC) in stage IV metastatic malignant melanoma.
    Hersh, EM
    Weber, J
    Powderly, J
    Yellin, M
    Kahn, K
    Pavlick, A
    Samlowski, W
    Nichol, G
    O'Day, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 712S - 712S
  • [32] A 2-stage controlled phase 1/2 study of STA-4783 in combination with paclitaxel in patients with advanced metastatic melanoma.
    Powderly, J
    Khan, K
    Richards, J
    Urba, W
    McLeod, M
    Dahl, T
    Sherman, ML
    O'Day, S
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 725S - 725S
  • [33] A Phase II Study of Irofulven (MGI 114) in Patients with Stage IV Melanoma
    A. Scott Pierson
    Peter Gibbs
    Jon Richards
    Paul Russ
    S. Gail Eckhardt
    Rene Gonzalez
    Investigational New Drugs, 2002, 20 : 357 - 362
  • [34] A PHASE-II STUDY OF DIBROMODULCITOL (DBD) IN STAGE-IV MELANOMA
    HOPKINS, J
    RICHARDS, F
    CASE, D
    POPE, E
    JACKSON, DV
    STUART, JJ
    MUSS, HB
    WHITE, DR
    COOPER, MR
    SPURR, CL
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1984, 7 (05): : 555 - 556
  • [35] A phase II study of Irofulven (MGI 114) in patients with stage IV melanoma
    Pierson, AS
    Gibbs, P
    Richards, J
    Russ, P
    Eckhardt, SG
    Gonzalez, R
    INVESTIGATIONAL NEW DRUGS, 2002, 20 (03) : 357 - 362
  • [36] Temozolomide (TMZ) plus thalidomide (THAL) as adjuvant therapy in patients with stage III and stage IV malignant melanoma.
    Hwu, WJ
    Coit, D
    Jaques, D
    Panageas, KS
    Lamb, LA
    Quinn, CJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 728S - 728S
  • [37] A Phase II multicenter trial to evaluate combination ipilimumab and high-dose IL-2 in patients with unresectable stage III and IV melanoma.
    Kaufman, Howard
    Wang, Jiafeng
    Curti, Brendan D.
    Clark, Joseph
    Ernstoff, Marc S.
    Silk, Ann
    Mehnert, Janice M.
    Zloza, Andrew
    Shih, Joe
    McDermott, David F.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [38] Phase II trial of sequential temozolomide (TMZ) and high-dose bolus (HOB) IL-2 in patients with AJCC stage IV melanoma.
    Tarhini, A
    Agarwala, SS
    Gooding, W
    Cai, C
    Kirkwood, JM
    Stover, LL
    Blair, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 722S - 722S
  • [39] A phase 2 study of talabostat/docetaxel in advanced NSCLC.
    Cunningham, C
    Richards, D
    Salgia, R
    Leonard, R
    Raju, R
    Berman, B
    Anthony, S
    Yang, ZJ
    Gregoire, L
    Haltom, E
    Uprichard, MJ
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9056S - 9057S
  • [40] Combined treatment with dacarbazine, cisplatin and interferon a in metastatic melanoma.
    Tessier, MH
    Mansat, E
    Legoux, B
    Litoux, P
    Dreno, B
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 1996, 123 (09): : 538 - 542
12345